COMMENTARY
Supply Woes Plague All 7 New Biosimilar Ingredients Listed since 2023
By Shinya Sato November 16, 2026
Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar debuts on the NHI price list between 2023 and 2026 have experienced significant launch delays…

LATEST

November 16, 2026
A wave of newly NHI-listed medicines hit the Japanese market on November 13, with Eisai, Janssen Pharmaceutical (J&J), Takeda Pharmaceutical, and other drug makers announcing launches of treatments spanning Alzheimer’s, cancer, psoriasis, and epilepsy.Eisai and its US partner Biogen launched…
November 16, 2026
A Japanese public-private policy subgroup on drug discovery is set to finalize a summary of its discussions within the next one to two weeks, with proposals on drug pricing to be forwarded to a key…
November 16, 2026
Japan’s health ministry has named Sawai Pharmaceutical, Towa Pharmaceutical, and 36 other companies as its highest-rated generic makers for their efforts to ensure stable supplies — marking the first public disclosure of company ratings under…
By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Tatsuya Otsuka

On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…

By Hayate Horiguchi

Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA